Chiasma Inc

Chiasma — Technical Presentation (November 2020)

12 slides from Chiasma's technical presentation, Nov 18, 2020

  1. Slide 1: Phase 3 MPOWERED Trial Top-line Results

    Phase 3 MPOWEREDTM Trial Top-line Results November 18, 2020 Exhibit 99.1

  2. Slide 2: Forward-looking statements

    These slides and the accompanying presentation contain forward-looking statements and information. The use of words such as “may,” “might,” “will,” “should,” “expect,” “plan,” “anticipate,” “believe,” “estimate,” “project,” “intend,” “future,” “potential,” or “continue,” and other similar expression

  3. Slide 3: MYCAPSSA is FDA Approved and is Commercially Available in the U.S.

    MYCAPSSA is FDA Approved and is Commercially Available in the U.S. Full prescribing information available at www.MYCAPSSA.com MYCAPSSA is a somatostatin analog indicated for long-term maintenance treatment in acromegaly patients who have responded to and tolerated treatment with octreotide or lanreo

  4. Slide 4: Acromegaly Market Overview

    Acromegaly Market Overview Octreotide and lanreotide injections are broadly used as first-line pharmacological treatments Acromegaly is a rare disease most often caused by a benign pituitary tumor and characterized by an excess of growth hormone and insulin-like growth factor-1 hormone. Treatment op

  5. Slide 5: Injections Carry Significant Treatment Burdens

    experience pain during injection; half of these experienced continuing pain days later Injections Carry Significant Treatment Burdens1 Pain Suboptimal Symptom Control Lost Workdays Emotional Impact Injection Site Reactions Hardness (48%), nodules (38%), swelling (28%), bruising (16%) and inflammatio

  6. Slide 6: MPOWERED Trial Positive: Met Primary Non-inferiority Endpoint

    MPOWERED Trial Positive: Met Primary Non-inferiority Endpoint MYCAPSSA (octreotide capsules) was shown to be non-inferior to long-acting injectable somatostatin analog injections (SSAs)* in maintenance of biochemical response for acromegaly patients. * Octreotide LAR and lanreotide autogel

  7. Slide 7: MPOWERED Non-inferiority Study Design

    MPOWERED Non-inferiority Study Design Last Injection Day (-28) Screening First Dose 6-Month Run-in Phase Responders Randomized to 9-Month Controlled Phase (RCT) Open Label Extension Follow for safety and efficacy 60% (55 pts) 40% (37 pts) Non-Responder Sub-study or Non-Responders Screening phase up

  8. Slide 8: Higher Baseline IGF-1 Levels in the MYCAPSSA Arm Compared to Injectable SSA Arm

    Higher Baseline IGF-1 Levels in the MYCAPSSA Arm Compared to Injectable SSA Arm MYCAPSSA Injectable Long-acting SSAs Total (N=55) Total (N=37) Week 26 IGF-1 (categorical) (n [%]) ≤ 1 x ULN 37 (67%) 29 (78%) > 1 to < 1.3 x ULN 12 (22%) 8 (22%) ≥ 1.3 x ULN 6 (11%) 0 (0%) Week 26 IGF-1 (ULN) Mean (SD)

  9. Slide 9: MYCAPSSA is Non-inferior to Long-acting Injectable SSAs

    MYCAPSSA is Non-inferior to Long-acting Injectable SSAs Achieved the pre-specified non-inferiority margin of -20% Primary Endpoint: IGF-1 Time Weighted Average (TWA)1 throughout the RCT phase < 1.3 x ULN 1 TWA response represents an integrated measure of efficacy across time. It is derived as the ar

  10. Slide 10: Mean IGF-1 Levels Were Maintained Within Normal Limits

    Mean IGF-1 Levels Were Maintained Within Normal Limits Baseline of RCT Baseline of RCT End of Treatment End of Treatment

  11. Slide 11: MYCAPSSA Appeared to be Safe and Well Tolerated

    MYCAPSSA Appeared to be Safe and Well Tolerated MYCAPSSA Injectable Long-acting SSAs Subjects with: n % n % At least one TEAE 39 70.9 26 70.3 Treatment-Related TEAE 19 34.5 15 40.5 SAEs 3 5.5 3 8.1 Severe TEAEs 5 9.1 4 10.8 TEAE Leading to Study Drug Discontinuation(1) 1 1.8 0 0 SAEs - Serious Adver

  12. Slide 12: MYCAPSSA Appeared Safe and Well Tolerated

    MYCAPSSA Appeared Safe and Well Tolerated MYCAPSSA Injectable Long Acting SSAs Total (N=55) Total (N=37) Gastrointestinal disorders Flatulence 14 (25.5) 8 (21.6) Nausea 11 (20.0) 3 (8.1) Diarrhea 6 (10.9) 5 (13.5) Abdominal pain 5 (9.1) 3 (8.1) Constipation 3 (5.5) 5 (13.5) Infections & infestations

Chiasma — Technical Presentation (November 2020) on 6ix